tbuckley/cabot-search huggingface dataset:
Abstract 16391: Zfp148 Deficiency Reduces Lesional Macrophage Proliferation and Atherosclerosis in Mice by Activating P53
Authors: Volkan I Sayin
Journal: Circulation (2015)

Introduction: Cell proliferation and cell cycle control mechanisms are believed to play central roles in the pathogenesis of atherosclerosis. The transcription factor Zinc finger protein 148 (Zfp148) was recently shown to maintain cell proliferation under oxidative conditions by suppressing p53, a checkpoint protein that arrests proliferation in response to various stressors. It is established that inactivation of p53 accelerates atherosclerosis, but whether increased p53 activation confers protection against the disease remains to be determined. Hypothesis: We aimed to test the hypothesis that Zfp148 deficiency reduces atherosclerosis by unleashing p53 activity. Methods and Results: Mice harbouring a gene-trap mutation in the Zfp148 locus (Zfp148gt/+) were bred onto the Apoe-/- genetic background and fed a high-fat or chow diet. Loss of one copy of Zfp148 markedly reduced atherosclerosis without affecting lipid metabolism. Bone marrow transplantation experiments revealed that the effector cell is of hematopoietic origin. We next investigated whether p53 is part of the underlying mechanism. Peritoneal macrophages and atherosclerotic lesions from Zfp148gt/+Apoe-/- mice showed increased levels of phosphorylated p53 compared to controls, and atherosclerotic lesions contained fewer proliferating macrophages. Zfp148gt/+Apoe-/- mice were further crossed with p53-null mice (Trp53-/-). There was no difference in atherosclerosis between Zfp148gt/+Apoe-/- mice and controls on a Trp53+/- genetic background, and there was no difference in levels of phosphorylated p53 or cell proliferation. Conclusions: Zfp148 deficiency increases p53 activity and protects against atherosclerosis by causing proliferation arrest of lesional macrophages. The protective effect is entirely dependent on p53 and suggests that drugs that increase p53 activity may be useful in the treatment of atherosclerosis.
PLoS Medicine Issue Image | Vol. 4(2) February 2007
Journal: PLoS Medicine (2007)

Schematic image of neuraminidase, a protein found on the surface of influenza virus. Neuraminidase comes in several versions that differ between viral strains. One of them, the N1 version, is common to both the H5N1 "avian flu" strain and the more common seasonal H1N1 strains. The research article by Sandbulte and colleagues examines whether mice and humans who have been exposed to H1N1strains could develop immunity that provides some level of protection against the H5N1 strain. The implications of the findings are discussed in an accompanying Perspective article by Gillim-Ross and Subbarao.
Gynecological and Obstetrical Pathology with Clinical and Endocrine Relations
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EXPERIMENTAL CIRRHOSIS OF LIVER.
Journal: JAMA (1900)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A phase I study of cabozantinib plus nivolumab (CaboNivo) and cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other genitourinary (GU) tumors.
Authors: Andrea B. Apolo, Amir Mortazavi, Mark N. Stein, Nicole N. Davarpanah, Rosa Maria Nadal, Howard L. Parnes, Yangmin M. Ning, Deneise C Francis, Lisa M Cordes, Marilise Anne Berniger, Seth M. Steinberg, Piyush K. Agarwal, Mohammadhadi H. Bagheri, Swati Nanda, Paul Monk, Tiffany Lancaster, Tina Moore, Rene Costello, Donald P. Bottaro, Sumanta K. Pal
Journal: Journal of Clinical Oncology (2017)

4562 Background: We report the safety and clinical activity of the combination of CaboNivo and CaboNivoIpi in pts with mUC and other mGU tumors (NCT02496208). Methods: In this phase I trial 30 pts were treated in 4 dose levels (DL) for part 1 (CaboNivo) and 18 pts were treated in 3 DL for part 2 (CaboNivoIpi). Pts received Cabo PO daily and Nivo IV (part 1) with Ipi 1mg/kg x 4 doses q3wks (part 2). A mUC and a renal cell carcinoma (RCC) expansion cohort of CaboNivo has initiated enrollment. Tumors were assessed for overall response rate (ORR) q8wks (RECIST 1.1). Adverse events (AEs) were graded (G) by NCI-CTCAE v4.0. Results: From 7/22/15 to 12/31/2016, 48pts (CaboNivo N = 30; CaboNivoIpi N = 18) (mUC N = 19; bladder urachal N = 4; bladder squamous cell carcinoma (bSCC) N = 2; germ cell tumor (GCT) N = 4; castrate-resistant prostate cancer (CRPC) N = 9; RCC N = 2, sarcomatoid RCC N = 2, Sertoli cell N = 1, and trophoblastic tumor N = 1 were treated. Median age was 58 (range 35-77), 41 (85%) were male. Common treatment-related G1/2 AEs for CaboNivo: ALT increase (67%), fatigue (63%), diarrhea (60%), hypothyroidism (57%); CaboNivoIpi: fatigue (72%), diarrhea (61%), anorexia (61%); Grade 3 AEs for CaboNivo: hypertension (23%), neutropenia (17%), hypophosphatemia (13%), lipase increase (10%), fatigue (7%), aseptic meningitis (3%); CaboNivoIpi: hypophosphatemia (19%), hypertension (19%), fatigue (13%), hyponatremia (13%), nausea (13%), lipase increase (11%), colitis (6%); G4 CaboNivo: lipase increase (7%) thrombocytopenia (3%); CaboNivoIpi lipase increase (6%) There were no G5 toxicities, no DLTs. 43 pts were evaluable for response: ORR was 30% 13/43 [3 CR (2 mUC, 1 bSCC); 10 PRs (4 mUC, 2 penile, 1 sarcomatoid RCC, 1 urachal, 1 CRPC, 1 bSCC)]. ORR for CaboNivo 39% (mUC 44%); CaboNivoIpi 18% (mUC 29%). 11/13 (85%) of responses were ongoing at cutoff. Conclusions: CaboNivo and CaboNivoIpi combinations were well tolerated with no DLTs and have durable efficacy in mGU tumors particularly mUC. Rare tumors such as bSCC, urachal, and penile cancers demonstrated response to the combination. Larger cohorts of mUC and rare GU tumors are ongoing. Clinical trial information: NCT02496208.
Adult (Not Internal) Medicine
Authors: Lee Goldman
Journal: Annals of Internal Medicine (1998)

Letters1 June 1998Adult (Not Internal) MedicineLee Goldman, MDLee Goldman, MDUniversity of California, San Francisco; San Francisco, CA 94143Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-11-199806010-00029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:My recent editorial stated not only the belief that the current name internal medicine is suboptimal but also that the new name should be adult medicine. It is not surprising that some would disagree with the need for any change in name and that even those who prefer a change might not agree on a single alternative. Dr. Block prefers to maintain internal medicine because of its “spectacularly illustrious tradition.” I do not debate the tradition, only whether such an argument is sufficient. Tradition is wonderful, but it should not stand in the way of needed change. Dr. ... Author, Article, and Disclosure InformationAuthors: Lee Goldman, MDAffiliations: University of California, San Francisco; San Francisco, CA 94143 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLow-dose (1 μg) adrenocorticotrophin (ACTH) stimulation as a screening test for impaired hypothalamo-pituitary-adrenal axis function: sensitivity, specificity and accuracy in comparison with the high-dose (250 μg) test 1 June 1998Volume 128, Issue 11Page: 958KeywordsAdolescent medicineHearingPediatricsPrimary care physicians ePublished: 15 August 2000 Issue Published: 1 June 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Exploding Bottles
Authors: Rowland L. Mindlin
Journal: JAMA (1963)

<h3>To the Editor:</h3> —The hazard of the exploding bottle is not restricted to the use of carbonated beverages in the tropics. A pneumatic cork-ejector has recently appeared on the scene. One evening this gift was put to use on a bottle of Chianti. Serious injury may have been avoided because the wine was a Chianti. The straw or raffia basket in which the bottle rested was functional as well as decorative, and the flying fragments of glass were contained in it. The only casualties were the tablecloth, the rug, and my gratitude for the gift. And, of course, the now-discarded pneumatic cork-ejector.
Abstract O.52: Infliximab Use And Cardiac Outcome in Infants ≤ 6 Months Old: A Two Center Retrospective Study
Authors: Adriana Tremoulet, Andrea Salgado, Negar Ashouri, Erika Berry, Sonia Jain, Xiaoying Sun, Jane C Burns
Journal: Circulation (2015)

Background: Incomplete KD, as well as a higher incidence of CAA, has been reported to occur more commonly in infants ≤ 6 months (mos), but only small case series have been published. We characterized the KD course in infants ≤6 mos and compared to outcomes in KD pts &gt;6 mos. Methods: We retrospectively reviewed the course of 88 subjects ≤ 6 mos diagnosed with KD between January 2004 and December 2013 at Children’s Orange County (CHOC) and Rady Children’s Hospital San Diego (RCHSD) and compared to 632 subjects &gt;6 mos at RCHSD. Complete and incomplete KD cases were defined based on the 2004 AHA guidelines. Subjects were classified by coronary artery (CA) status (normal, dilated, or aneurysmal CA based on RCA and LAD measurements) and by Z-score (RCHSD only). IVIG resistance was defined as fever ≥38C at least 36 hours after completion of IVIG. Fisher’s Exact test was used for comparisons. Results: Of the 88 infants, 62 (70.4%) were male and 76 (86.3%) were treated at ≤ 10 days of illness. Treatments in the 88 pts were as follows: IVIG responder: 55(62.5%); IVIG resistant: 13(14.7%); infliximab for cardiac indications: 16 (18.2%); late treatment &gt;10days: 2 (2.3%); not treated: 2 (2.3%). Infliximab was administered to a total of 27 pts (30.7%) and was well-tolerated with rash as the only adverse event in 1 pt. Worst CA status was “normal” in 37 (42.1%), dilated in 29 (32.9%), aneurysm in 15 (17.1%) and giant aneurysm in 7 (7.9%) pts. Of the 48 pts at RCHSD who presented within the first 10 days of illness, only 26 (54.2%) had a Z-score &lt;2.5. Of these 26 pts, 7(26.9%) went on to have a subsequent Z score ≥ 2.5. Comparing the ≤6 mos vs. &gt; 6 mos RCHSD cohorts, there were no significant differences in number of pts treated within the first 10 days of illness (48/53, 90.5% vs. 545/632, 86.2%) or pts having incomplete presentations (12/53, 22.6% vs. 106/632, 16.8%). Conclusions: There were no significant differences in the rate of incomplete KD or rate of diagnosis within the first 10 days of illness in children ≤6 mos vs. &gt;6 mos. Infliximab use in 30.7% of the ≤6 mos old pts was safe. Infants ≤6 mos had a high rate of aneurysms (22/88, 25%) despite timely diagnosis and treatment. Better treatments are needed for this high risk group of KD pts.
Acupuncture anesthesia in the People's Republic of China Implications for American medicine
Authors: J. J. Bonica
Journal: JAMA (1974)

During the past three decades, Dr. John J. Bonica has been greatly involved in the pioneering of American anesthesiology as a teacher, clinician, and investigator. He has devoted much of his professional effort to the study of pain mechanisms and the management of chronic pain syndromes. In 1953, he published<i>The Management of Pain</i>, a 1,500-page volume that has become established as the "bible" of pain. He has also published more than 100 articles on the subject and has recently edited two monographs reporting most recent research on pain. Dr. Bonica is Chairman of the Ad Hoc Committee on Acupuncture of the National Institutes of Health and a similar committee of the American Society of Anesthesiologists. Last year, he was selected by the Committee on Scholarly Communication with the People's Republic of China of the National Academy of Sciences to be a member of the first official American medical delegation to visit the People's Republic of China, and was given the responsibility of evaluating acupuncture and anesthesia as practiced in that country.
Anaerobic septicemia from thrombophlebitis of the internal jugular vein. Successful treatment with metronidazole
Authors: R. J. Mitre
Journal: JAMA (1974)

A patient had anaerobic septicemia associated with thrombophlebitis of the internal jugular vein. This infection has characteristic features, and diagnosis is not difficult, provided the physician is aware of the syndrome. A prompt clinical response to metronidazole occurred after other antibiotics commonly recommended for anaerobic infections had failed. This case highlights recent observations that suggest an important role for metronidazole in anaerobic bacterial, as well as anaerobic protozoal, infections. (<i>JAMA</i>230:1168-1169, 1974)
Tribute to Dr. Jerome T. Syverton
Journal: JNCI Journal of the National Cancer Institute (1961)

Journal Article Tribute to Dr. Jerome T. Syverton Get access Members of the National Advisory Cancer Council Members of the National Advisory Cancer Council Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 26, Issue 4, April 1961, Page ii, https://doi.org/10.1093/jnci/26.4.ii Published: 01 April 1961
THE WHITMAN LOOP OPERATION FOR EQUINOVALGUS
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2888: Targeting the fatal pediatric brain tumors AT/RT and DIPG with the DNA binding agent quinacrine
Authors: Harpreet Kaur, Huizi Guo, Peter Green, Sepehr Akhtarkhavari, Smit Shah, Charles G. Eberhart, Eric H. Raabe
Journal: Cancer Research (2019)

Abstract Atypical teratoid/rhabdoid tumors (AT/RT) and diffuse intrinsic pontine glioma (DIPG) are incurable pediatric brain tumors. Developing new targets and novel therapeutics are urgently needed. We have previously shown that multiple primary brain tumors and cell lines express increased amounts of the epigenetic modifier high mobility group AT-hook 2 (HMGA2). HMGA2 is a DNA-binding oncoprotein that regulates transcription during normal embryogenesis and in cancer stem cells. Targeting HMGA2 using short hairpins significantly decreased AT/RT and glioma growth and increased survival of xenografted mice. We hypothesized that pharmacological inhibition of HMGA proteins using DNA minor-groove binding drugs like quinacrine will decrease AT/RT and DIPG growth due to displacement of HMGA proteins from the DNA. We used quinacrine in ten patient-derived cell lines: five AT/RT (BT37, CHLA-05, CHLA-06, BT-12, CHLA-266) and five DIPG (JHHDIPG1, SUDIPGXIII, JHHDIPG16A, SF7761, HSJD-007). Quinacrine has been used in millions of humans to treat malaria and parasitic infections, has a well-known safety profile and can penetrate the brain. Using quinacrine fluorescence as a surrogate, we can achieve therapeutically efficacious micromolar concentration of quinacrine in the mouse and zebrafish brain after oral administration without overt toxicity. In both tumor cell lines, quinacrine causes a dose-dependent reduction in growth (MTS) and proliferation (BrdU) compared to vehicle-treated cells (P&amp;lt;0.01). Treatment of both tumor lines with quinacrine significantly increased apoptosis (cleaved caspase-3 and cleaved PARP) compared to control cells (P&amp;lt;0.01). Quinacrine had no effect on growth of normal hindbrain cells. Our results suggest that minor groove binding drugs like quinacrine are a viable potential treatment strategy for these lethal tumors. Ongoing studies include validating the in vivo efficacy of quinacrine using zebrafish and mouse models of AT/RT and DIPG. Future studies are aimed at investigating the mechanism of quinacrine in these devastating tumors. Citation Format: Harpreet Kaur, Huizi Guo, Peter Green, Sepehr Akhtarkhavari, Smit Shah, Charles G. Eberhart, Eric H. Raabe. Targeting the fatal pediatric brain tumors AT/RT and DIPG with the DNA binding agent quinacrine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2888.
THE TOLL OF THE AUTOMOBILE
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Alcohol-induced genital pain in recurrent Hodgkin's disease
Authors: W. B. Ershler
Journal: JAMA (1979)

THE ASSOCIATION between alcohol-induced pain and Hodgkin's disease was first noted by Hoster<sup>1</sup>in 1950. Several series<sup>2-7</sup>have confirmed this association; however, pruritus, paresthesia, cough, and general malaise have also been reported.<sup>3</sup>Patients with other malignant<sup>5</sup>and nonmalignant conditions<sup>5,6</sup>have been described to have alcohol-induced pain. We examined a patient whose complaint of alcohol-induced pain in the labia majora led to the diagnosis of recurrent Hodgkin's disease. <h3>Report of a Case</h3> A 34-year-old woman was admitted to the hospital because of genital pain. Eight years before admission, an intermittent pain in the right hip developed, which characteristically was induced by the ingestion of alcohol, even in small quantities. She had anterior cervical lymphadenopathy, and a biopsy specimen demonstrated nodular sclerosing Hodgkin's disease. Lymphangiogram demonstrated intra-abdominal lymph node enlargement, and bone roentgenogram findings were consistent with findings of Hodgkin's disease in the right side of the
Index of Subjects, Volume 29
Journal: JNCI Journal of the National Cancer Institute (1962)

Journal Article Index of Subjects, Volume 29 Get access JNCI: Journal of the National Cancer Institute, Volume 29, Issue 6, December 1962, Pages 1189–1195, https://doi.org/10.1093/jnci/29.6.1189 Published: 01 December 1962